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Purpose: Maintenance of  hemodialysis access grafts represents an enormous ocial and 
clinical problem. Current grafts and graft salvage techniques are inadequate. Conse- 
quently, there has been increasing interest in the use of  minimaUy invasive catheter 
techniques to prophylactically treat stenoses in functioning arteriovenous grafts. Prophy- 
lactic balloon angioplasty has been widely suggested as prolonging assisted primary 
patency. We have performed a prospective randomized trial to compare patients who 
underwent percutaneous transluminal angioplasty (PTA) for graft stenoses > 50% with a 
control group that received no intervention. Out hypothesis was that to be efficacious a
minimal benefit of  20% prolongation in patency would be necessary. 
Methods- Color flow duplex scanning was used to detect >50% stenoses in ftmctioning 
expanded polytetrafluoroethylene grafts. Patients were then subjected to confirmatory 
angiographic evaiuation. Those who had angiographic stenoses > 50% were randomized 
to balloon angioplasty or observation. Patients were followed-up with duplex scanning 
every 2 months. Statistical analysis was performed using the Kaplan-Meier technique. 
Although demographically the patient groups were weh matched, there were more prior 
interventions and concurrent central stenoses in the treatment group. Outcomes were 
graft thrombosis, graft dysfunction that precluded ialysis, and six or more PTA proce- 
dures within 18 months. 
Results- In the treatment and observation groups, the 6-month patency rates were 69% ± 
7% and 70% ± 7%, respectively. The 12-month patency rates for the treatment and 
observation groups were 51% - 6% and 47% -+ 4%, respeetively. There was no significant 
difference between these two groups (p = 0.97), with an 80% confidence limit for 
detection of  a difference greater than 20%. 
Conclusions: This study demonstrates that a generic approach of  PTA to treat all 
polytetrafluoroethylene grafts with stenoses > 50% does not prolong patency and cannot 
be supported. (J Vasc Surg 1997;26:382-92.) 
The hemodialysis population in the United States 
continues to grow at approximately 10% per year. 1 
Polytetrafluoroethylene grafts are the dialysis mode 
in 80% of  this patient group and represent the most 
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Dialysis is required for some 120,000 Americans 
with end-stage renal disease. 3 
Unfortunately, expanded polytetrafluoroethylene 
(ePTFE) bridge grafts are fraught with complications 
and their durability is limited, with the average dura- 
tion of patency being only 18 months. 4-7 Failure 
occurs predominantly from stenoses that develop at 
the venous anastomosis a  a consequence of aggres- 
sive neointimal hyperplasia, s~9 Although this lesion is 
notoriously ditficult o dilate, there has been an in- 
creasing number of reports that suggest that angio- 
plasty is both important in prolonging raft patency 
as well as being an adjunctive measure in opening the 
thrombosed graft3 °-12 Schwab, ~° in a landmark 
1989 report, suggested that early detection and 
treatment of fistula stenoses would prolong graft 
patency, preserve alternate sites, and reduce the 
number of central venous cannulations for acute di- 
alysis. Most studies that have supported prophylactic 
intervention, although retrospective in design, have 
suggested a statistically significant benefit and have 
had a profound effect on the approach to manage- 
ment of the failing graft. Consequently, endovascular 
techniques are being increasingly advocated as a 
method of improving secondary patency rates. An- 
gioplasty, stenting, and thrombolysis have all been 
reported as providing etficacy and have been widely 
adopted as the new gold standard for the manage- 
ment of arteriovenous grafts, nq5 Indeed, the con- 
cept of prophylactic ntervention has been born as a 
consequence of the development of these minimally 
invasive interventions and has led to the proliferation 
of graft surveillance protocols to detect early steno- 
ses. 10,16-26 Although this concept initially appears 
reasonable, it is predicated on the belief that an 
intervention exists that is effective in prolonging raft 
patency. This study was initiated to test the assump- 
tion that balloon angioplasty of hemodialysis-related 
stenoses (>50% diameter) would improve patency 
rates when compared with untreated, similarly ste- 
notic ePTFE arteriovenous grafts. 
PATIENTS AND METHODS 
During the period December 1993 to November 
1996, all chronic hemodialysis patients with ePTFE 
grafts in a single inner-city dialysis unit were screened 
as candidates for enrollment in this trial. By virtue of 
the location of the unit, this was a preselected group 
ofpatients, largely representing an inner-city popula- 
tion, whose demographics are provided in Table I. 
Reasons for nonenrollment included patient refusal, 
a contrast dye allergy, or a nonfunctioning ePTFE 
graft. Data on demographics, comorbidities, and dl- 
Table I. Patient demographics 
and comorbidities 
Observ ation PTA 
Men 14 17 
Women 18 15 
Age (mean -+ SD) 58 -+ 11 56 -+ 13 
Age (range) 35 to 74 34 to 72 
Race 
Black (%) 91 94 
White (%) 3 ó 
Oriental (%) 3 0 
Hispanic (%) 3 0 
Comorbidities 
Diabetes (%) 38 41 
Hypertension (%) 91 82 
PVD (%) 9 19 
CASHD (%) 19 28 
Smoking (%) 38 25 
PVD, Peripheral vascular disease; CASHD, coronary arterioscle- 
rotic heart däsease. 
alysis access history were obtained from review of the 
clinic dialysis records. Other forms of access not 
cvaluated in this study included Brescia-Cimino fis- 
tulas and bovine carotid artery heterografts. The de- 
sign of the study is demonstrated in Fig. 1. Approval 
for this study was obtained from the Human Investi- 
gations Committee at Emory University. A full, in- 
formed consent was obtained from each patient. All 
patients in the study underwent color flow duplex 
imaging (CDI) of the entire graft (arterial anastomo- 
sis, midgraft, venous anastomosis, outflow to the 
limits of visualization). Those patients who had a 
stenosis >-50% (at any location) by CDI were sub- 
jected to angiographic study that included the arte- 
rial inflow, entire graft, and entire outflow from the 
venous anastomosis to the right atrium. It was 
thought hat paticnts with stenoses <50% by CDI 
could not ethically bc subjected to angiographic eval- 
uation. Therefore, the false-negative rate by CDI 
cannot be determined. 
CDI. Grafts were examined with a Quantum 
QAD 1 color flow duplex scanner, using a 7.5-MHz 
transducer and 18-degree stand-oft wedge. Pafients 
were positioned on an examination table with the 
extremity abducted and externally rotated. The per- 
cent stenosis was determined by measuring the diam- 
eter of the stenotic flow channel (s) vcrsus the diam- 
eter of the normal graft (n) using the following 
formula: [1 - (s/n)] × i00 = percent stenosis of the 
graft. Assessment of flow throughout the graft was 
measured by Dopplcr interrogation. Mean peal< sys- 
tolic and end diastolic velocities (cm/sec) were mea- 
sured over four cardiac cycles and averaged. The 
diameter (d) of a nonstenotic, nondilated midpor- 
JOURNAL OF VASCULAR SURGERY 
384 Lumsden et al. September 1997 
Dialysis at study dialysis unit 
Functioning upper arm ePTFE graft 
L 
Duplex ultrasound scan 
1 
> 50% stenosis 
1 
Biplanar Angiography 
conflrmation of > 50% stenosis 
Randomization 
Observation 
Q 3 month Duplex 
PTA 
Q3month duplex scan 
Repeat PTA for >50% stenosis PRN 
Follow to Outcome 
Fig. 1. Study design. 
tion offlow channel was measured for the purpose of 
calculating "normal" flow rates. The peak systolic 
and end diastolic flow rates (ml/min) were calcu- 
lated using the following formula: (¢rd 2) + 4 × 
average velocity × 60. 
Patients were eligible for CDI imaging regardless 
of  whether they exhibited any signs or symptoms of 
graft dysfunction. However, for the purposes of this 
trial, potential graft dysfunction i cluded an elevated 
recirculation ratio ( > 15 %) or elevated venous dialysis 
pressure (>240 mm Hg). To compare graft function 
in both treatment and control groups, we used a 
panel of functional tests: venous pressure during di- 
alysis at 400 tal/min flow rate, urea recirculation, 
and duplex measurement of flow volumes. Measure- 
ments of recirculation levels were performed on the 
same day as the routine CDI, as previously described. 8 
Fistulography. Digital angiographic images of 
the graft, arterial inflow, and venous outflow to the 
right atrium were recorded using the Phillips DVI-S 
system. Using a 5F micropuncture set (Cook Inc., 
Bloomington, Ind.), the fistula was punctured 5 cm 
from the arterial end, and a 5F catheter was insertcd. 
Radiographic ontrast medium was then injected, 
and digital subtraction angiograms of the fistula and 
the venous drainage to the right atrium were re- 
corded on a 512 digital matrix (DVI-S system, Phil- 
lips Medical Systems, NA, Eindhoven, The Nether- 
lands). Angiograms involving the arterial anastomosis 
of the fistula were obtained either by compressing 
the graft during injection of the contrast medium or 
by direct injection of contrast medium into the bra- 
chial artery through a 3F catheter. The digital angio- 
grams were recorded on x-ray film, and the stenosis 
within the fistula or veins was measured using an 
electronic aliper (Sandhill Scientific Inc., Littleton, 
Colo.). The longitudinal diameter at the point of  
greatest stenosis was compared with that of the clos- 
est normal adjacent lumen. 
The percent stenosis by fistulography was defined 
as: 
Longitudinal diameter 
of  the stenoscd segment 
× 100 
Longitudinal diameter of  an 
adjacent nonstcnosed segment 
Randomizat ion procedure. All patients con- 
firmed by angiographic evaluation to havc a stenosis 
>50% within the graft or at the anastomoscs were 
randomized by drawing cards to either no interven- 
tion or to percutaneous transluminal angioplasty 
(PTA). 
Angioplasty procedure. I f  a stenosis > 50% was 
identified, the SF cathcter was exchanged for a óFor  
7F introducer sheath (Pinnacle sheath, Meditech, 
Watertown, Mass.) and a 0.035-inch angled tip glide 
wire (Meditech) was inserted through the sheath and 
advanced undcr direct vision across the stenosis into 
the distal venous or arterial system. An appropriately 
sized angioplasty balloon (Ultra-thin or Blue Max, 
Meditech) was selected (gcnerally ovcrsizing by 1 to 
2 mm). High-pressure balloons were used bccause 
they are frequently required to dilatc resistant steno- 
ses. The balloon was inflated until all waisting was 
eliminated or to the maximum prcssurc recom- 
mended by the manufacturer (17 atm for the Ultra- 
thin and 25 atm for the Blue Max). 
Follow-up. All of the patients were cvaluated 
three times a week at the dialysis centcr. Estimates of 
patency wcre therefore accurate to within approxi- 
mately 3 days. CDI was performed every 2 months 
on all grafts. Paticnts randomized to the trcatment 
arm in whom >50% diameter restenosis developed as 
determined by duplex scanning were subjectcd to 
repeat angiography and repeat angioplasty if >50% 
stenosis was confirmed. Patients who required more 
than six PTA procedures in less than 18 months were 
deemed to be treatment failures and »vere considered 
to have had a primary outcome vent. 
Statistical analysis. Statistical analysis was per- 
formed using Kaplan-Meier analysis. A p value less 
than 0.05 was considcred significant. 
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Table II. Background ata--graft type, 
location, and prior revisions 
Observation PTA p 
Upper-arm graft 22 23 
Upper-arm loop 1 0 
Forearm loop 8 7 
Forearm straight 1 1 
Groin loop grafts 0 1 
4-7 mm ePTFE 30 29 
6 mm ePTFE 2 3 
No. ofprior revisions 
Surgical 1.06 -+ 1.48 1.6 ± 1.7 0.11 
PTA 0.52 _+ 1.02 0.5 ± 0.8 0.53 
Outcomes. The primary outcome event was 
functional graft failure defined as thrombosis or im- 
paired flow such that dialysis was not feasible. During 
the course of  the study, a third outcome was estab- 
lished, namely, of a patient requiring more than six 
PTA procedures in less than 18 months to maintain 
luminal dimension >50% diameter. 
RESULTS 
Of  17.0 patients screened for the study, 136 
(80%) had ePTFE grafts. Sixty-five patients were 
identified by CDI to have >50% stenoses and were 
referred for angiography. Of  these, 64 patients were 
confirmed to have eligible stenoses and were ran- 
domized--32 into the treatment arm (PTA) and 32 
into the nontreatment arm. Thirty-one of the pa- 
tients were men, and 33 were women. Fifty-nine of 
the patients were black, three were white, one was 
Asian, and one was Hispanic. Demographics and 
comorbiditles for each group are provided in Table I. 
Of  the 64 grafts, 36 of the ePTFE grafts were located 
in the left upper arm, 12 were in the right upper arm, 
12 were in the left forearm, three were in the right 
forearm, and one was in the right thigh. Eight of the 
grafts had a loop configuration, whereas the major- 
ity, 56, were straight (Table II). Both groups were 
well matched for age, distribution, and type of  graft. 
There were more ptior surgical revisions in the PTA 
group and fewer prior angioplasty procedures in the 
PTA group than in the observation group (Table II). 
The degree of stenosis and distribution of the steno- 
ses were similar (Table III), with the exception of a 
greater number of concurrent central venous steno- 
ses in the PTA group compared with the observation 
group (17 stenoses versus seven stenoses). 
Only eight of  the 64 patients (13%) had elevated 
urea recirculation ratlos. Two of these patients were 
in the treatment group and five were in the observa- 
Table II I . Severity and disttibution of 
angiographically documented stenoses 
Observation PTA 
Average % venous 67 ± 10 66 + 12 
stenosis (30 stenoses) (24 stenoses 
Average % midgraft 57 ± 8 60 + 10 
stenosis (16 stenoses) (17 stenoses 
Average % arterial 90 52 
stenosis (1 stenosis) (1 stenosis) 
Average % central 64 ± 14 67 ± 15 
stenosis (7 stenoses) (17 stenoses 
Table IV. Graft function by venous 
pressure measurements, recirculation, and 
duplcx determined flow volume 
Observation PTA 
Mean venous prcssure (mm Hg) 240 + 45 251.0 _+ 56 
Mean urea recirculation 10.2 + 5 9.8 ± 6 
Mean volume flow (tal/min) 
Peak systolic 2557 2300 
End diastolic 1550 1424 
Time to Outcome (days) 234 ± 271 246 ± 270 
tion group. Twenty-nine of the 64 patients (45%) 
had elevated venous dialysis pressures, all measured 
at blood flow rates greater than or equal to 400 
ml/min. Seventeen of these patients were in the 
treatment group and 12 were in the observation 
group, as seen in Table IV. 
In the treatment group, four patients died during 
the course of the study and vwo were lost to follow- 
up. One patient received acadaveric renal transplant. 
In the observation group, two patients died and one 
was lost to follow-up. For all patients, the mean 
duration of follow-up in the treatment group was 
462.1 _+ 68.4 days and was 463.6 + 69 days in the 
nontreatment group. 
The average number of transluminal angioplasty 
procedures performed pcr patient was 1.94 -+ 1.31 
(range, 1 to 6). Eight patients required greater than 
two PTA procedures, with two patients requiring six 
PTA procedures each (Fig. 2). 
The mean duration of patency of those grafts 
treated with balloon angioplasty was 246 + 270 
days. In the observation group, the mean duration of 
patency was 234 -+ 271 days. Life table analysis 
demonstrated a 6-month patency rate of 67% -+ 8% 
in the nontreatmcnt group and 63% -+ 9% in the 
treatment group (Table V). The 12-month patency 
rate was 48% _+ 9% in the nontreatment group and 
51% -+ 9% in the treatment group. There was no 
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Tab le  V ,  A .  Life tab le  patency  data - -observaUon 
Months 
Survival Median Median 
Patency Failure standard residual standard 
rate rate error lifetime error 
0 to 3 1.0000 0 0 11.3509 2.2904 
3 to ó 0.8033 0.1967 0.0720 16.5434 4.3230 
ó to 9 0.7007 0.2993 0.0837 - -  - -  
9 to 12 0.5929 0.4071 0.0911 - -  - -  
12 to 15 0.4743 0.5257 0.0952 - -  - -  
15 to 18 0.4312 0.5688 0.0958 - -  - -  
18 to 21 0.4312 0.5688 0.0958 ~ - -  
21 to 24 0.3737 0.6263 0.0988 - -  - -  
24+ 0.3737 0.6263 0.0988 - -  - -  
s igni f icant  di f ference in  patency  rates between these 
two groups  by  life tab le  analysis (p = 0 .97) .  Th is  is an  
80% conf idence  l imit  for  dc tect ion  o f  g reater  than  
20% dif ference between the  two groups  (Fig. 3). 
There  were  three  compl icat ions  o f  the  ang io -  
plasty procedure .  One  pat ient  had  dye cxt ravasat ion  
at the  ang iop las ty  site. Acutc  graft  th rombos is  devel-  
oped  in one  pat ient  dur ing  angioplasty ,  wh ich  was 
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Fig. 3. Life table analysis of graft patency data. 
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Table V, B. Life table patency data--angioplasty 
Patency Failure 
Months rate rate 
Survival Median Median 
standard residual standard 
error lifetime error 
0 to  3 1 .0000 0 0 13 .1024 6 .3714 
3 to ó 0.7667 0.2333 0 .0772 19 .6896 3 .4774 
6 to  9 0 .6970 0 .3030 0 .0845 - -  - -  
9 to  12 0 .5540 0 .4460 0 .0926 - -  - -  
12 to  15 0 .5158 0 .4842 0 .0937 - -  - -  
15 to  18 0 .4728 0 .5272 0 .0953 - -  - -  
18 to  21 0 .4230 0 .5770 0 .0974 - -  - -  
21 to  24  0 .4230 0 .5770 0 .0974 - -  - -  
24+ 0 .3525 0 .6475 0 .1036 - -  - -  
successfully reopened with urokinase during the 
same procedure. Another patient had intraprocedure 
chest pain, which was relieved by nitrogtycerin. 
There were no procedure-related complications in 
the observation group. 
A total of 42 lesions were located with CDI in the 
32 treated patients. Fifty-nine lesions were identified 
with angiography in this same group. This averages 
to 1.35 + 0.55 lesions per patient studied found by 
CDI and 1.83 + 0.76 lesions per graft demonstrated 
with angiography. A total of  44 lesions were identi- 
fied with CDI in 32 patients who were not treated. 
There were 54 lesions identified with angiography in
the observation group. This averages to 1.33 + 0.81 
lesions per graft studied with CDI and 1.69 + 0.85 
lesions per graft demonstrated byangiography. 
Using both the X 2 and unpaired t test, there was 
no significant difference in the number or distribu- 
tion of stenoses between the PTA and observation 
groups. Thcre wert slightly more prior surgical (p = 
0.11) and PTA (p = 0.53) procedurcs in the treat- 
ment group than in the obscrvation group (Table 
II). 
DISCUSSION 
Modern hemodialysis became feasible whcn 
Quinton et al. introduced the external arteriovenous 
shunt in 1960. 27 Recurrent hromboses, infections, 
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and occasional major bleeding episodes, however, 
prompted evelopment of the subcutaneous arterio- 
venous fistula by Brescia et al. in 1966. zs ePTFE 
grafts were first used as bridge conduits in 1976 and 
are currently the most popular method of establish- 
ing hemodialysis access in the United States. 4 De- 
spite their widespread use, there has been no im- 
provement in their durability since they were 
introduced clinically in 1976. 4 The mean duration of 
primary patency of these grafts is only 18 months, 
resulting in frequent hospital admissions for throm- 
bectomy, PTA, revision of the venous anastomosis, 
or new graft placement, s-7 Most grafts come to clin- 
ical attention at the time of graft thrombosis. How- 
erer, some functioning rafts are evaluated because 
of recurrent thromboses or fismla dysfunction (high 
venous pressures, elevated urea recirculation, poor 
flow rates) that results in impaired dialysis. 1°,n,18 26 
Unfortunately, surgical salvage of these grafts, typi- 
cally thrombectomy and patch angioplasty, results in 
only an additional 3 months of patency. 5 7 Indeed, 
surgical results are so dismal that others have sug- 
gested that the failed graft should be abandoned and 
that replacement rather than revision should be ad- 
vocated. 29 Such an approach, however, particularly 
in the young patient, could result in rapid exhaustion 
of access ites. Nevertheless, after grafts thrombose, 
there is no doubt that durability is significantly com- 
promised and new access placement is frequently 
necessary. Consequently, a reasonable approach 
would appear to be prophylactic ntervention: repair 
stenoses before graft failure. A variety of techniques 
have been developed to evaluate graft function or, 
more specifically, to detect graft dysfunction: venous 
outflow pressure measurement, urea recirculation, 
and outflow resistance) 8-2° With the advent of du- 
plex scanning, noninvasive imaging of the graft be- 
came feasible and stenoses could be directly mea- 
sured. 8,16,21 This technique is currently the gold 
standard for noninvasive valuation of the arterio- 
venous access grafts, and its accuracy has been previ- 
ously reported. 8 Clearly, an effective method for ste- 
nosis detection within the graft is now available, 
although remote stenoses, particularly within the 
subclavian vein, cannot be demonstrated by CDI. 
However, graft surveillance can only be justified ifan 
effective intervention is available that provides mean- 
ingful prolongation of graft patency. The null hy- 
pothesis in this study was that balloon angioplasty 
would provide such a benefit. We believed that ste- 
noses present in functioning rafts would likely be of 
lesser severity than those in occluded grafts and that 
stenoses detected by screening may represent a pop- 
ulation that is more amcnable to catheter-based in-
tervention (i.e., they may represent a group in which 
we believed PTA would have the best chance of 
success). Our hypothesis, therefore, was that early 
intervention and "prophylactic" angioplasty would 
prolong the patency of these functioning, but com- 
promised, arteriovenous grafts. 
Meaningful prolongation in graft patency was 
defined in this study for statistical purposes as an 
increase in patency of more than 20% in the treat- 
ment group compared with the control group. No 
statistically significant improvement was detected. 
Indeed, there was most likely no improvement in 
patency associated with prophylactic PTA. This oc- 
curred despite an average of 1.94 angioplasty proce- 
dures per patient during the study period. Clearly a 
significant cost, for no observed benefit. In examin- 
ing the two study populations, they were closely 
matched in age, sex, comorbidities, and type and 
location of the graft. There was a dittèrence in the 
number of concurrent central venous stenoses, with 
six stenoses in the observation group and 11 in the 
PTA group. There were no significant differences in 
the functional graft parameters measured: mean ve- 
nous pressure, mean urea recirculation, and peak 
systolic and end diastolic volume flow (Table IV). 
The latter would suggest that the additional central 
venous stenoses in the PTA group had little func- 
tional impact on the arteriovenous graft. 
Perhaps the most important question that arises is 
why angioplasty of venous stenoses works poorly. 
Davidson et al. 3° examined the immediate results of 
PTA in venous stenoses using intravascular ultra- 
sound. However, there was rapid recoil, which re- 
flects the elasticity of the lesion and may be one of 
the principal physical factors that limits the etficacy of 
angioplasty. In this respect, these lesions behave very 
differently from the more rigid, brittle, atheroscle- 
rotic arterial esions. Another source of error when 
evaluating the efficacy of angioplasty is the variability 
of stenotic lesions. Only Beathard 31 has attempted to
classify these lesions, and further attempts at classifi- 
cation are clearly necessary. It may weil be that PTA, 
as in the arterial system, is most efficacious for se- 
lected, short, focal lesions. 
Although this study casts some doubt on the role 
of PTA in treatment of these grafts, vascular surgeons 
cannot be proud of the patency rates of surgically 
implanted and revised grafts. Indeed, it is precisely 
because of the poor surgical results that much of the 
focus has been placed on catheter-based salvage. 32-37 
Traditional surgical therapy for occluded access 
grafts consists of thrombectomy with selective graft 
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revision. 4 Identif ication o f  a stenosis is based on 
tactilc fccdback from an embolectomy catheter, as 
weil as the lack o f  brisk prograde and retrograde 
bleeding. Usually, only one lesion is detected per 
exploration. This approach prolongs graft patency by 
an average o f  only 3 months.  The inherent limita- 
tions o f  such an approach are demonstrated by a 
recent prospective duplex and angiograph!c study in 
which we demonstrated that there is an average of  
1.3 stenoses in each graft by CDI  and 1.6 stenoses in 
each graft when studied with angiography.16 Indeed,  
similar results are noted in this report,  whcrc an 
average o f  1.84 and 1.69 lesions were noted in the 
observation and treatmcnt groups, respectively. It  
should come, therefore, as little surprise that identi- 
fying and treating only one lesion results in poor  
sccondary patency. Angiography alone at the time of  
th rombectomy identifies lesions in the entire system: 
arterial inflow to r ight atrium, s,38 These lesions are 
generally not  detected or treated during standard 
surgical thrombectomy.  We believe that given the 
frequency o f  synchronous lesions, angiography 
should be a component  o f  graf* revision. We believe 
that a combined surgical and catheter-based ap- 
proach is necessary. Given the findings in this manu- 
script, in which PTA o f  predominant ly  venous anas- 
tomot ic  stenoses is ineffective, we would  continue to 
advocate surgical revision o f  that anastomosis. How-  
erer, angiography and catheter-based approaches 
may be the only method by which remote lesions can 
be detccted and addressed. This approach is appeal- 
ing for several reasons: (1) it is an objective, quanti-  
tative method to determine the frequency and sever- 
ity o f  critical stenoses within the failed access graft; 
(2) remote and perigraft stenoses can be treated at 
the same sitting; (3) it avoids repeated violation o f  
planes until  surgical revision is necessary; (4) the 
current approach is inadequate; and (5) the de- 
scribed approach permits complementary use o f  en- 
dovascular and tradit ional surgical techniques. 
The intervention selected should be based on 
which is the most dficacious for each lesion, as well as 
which will provide the greatest durabil ity o f  each 
access ite. There may well be subsets ofstenoses that 
can be treated by PTA. One potential  weakness in 
the study is that there is a greater number  o f  prior 
interventions and central stenoses in the treatment 
group. This potential ly could adversely affect the 
outcome. This study, however, demonstrates that a 
generic approach o f  PTA to treat all PTFE grafts 
with stenoses >50% cannot be supported.  
A larger study to evaluate patients on the basis o f  
prior interventions and central stenoses may be nec- 
essary to d¢finitely address other potential  variables. 
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DISCUSSION 
Dr. S. T imothy  Str ing (Mobile, Ala.). This was a very 
nice presentation and a very timely subject. The anthors 
certainly are to be congratulated in trying to quantify the 
precursors of failure in the arteriovenous shunt and their 
potential treatment with endovascular methods. Too, the 
program committee is to be commended for having several 
papers on a not-so-popular subject hut a very necessäry 
subject on this program for those of us involved in the 
patient popuhtion pur before. Furthermore, Dr. Lumsden 
and his associates have helped confirm in a prospective 
manner our blas of experience that angioplasty or stent 
placement in the graft or venous outflow system is very 
much ineffective. This paper begins to dismiss the myth 
that is being purported ofendoväscular success. 
Several questions come to min& First, what are the 
physiologic data in an arteriovenous fistula that suggest a 
>50% stenosis, a hemodynamically significant lesion? Virere 
these grafts really, as you quotcd in the paper, compro- 
mised arteriovenous fi tulas, and if so, on what basis? Was 
the flow in ml /min  or any other parameters, uch as recir- 
culation time or increased venous pressure, useful as a 
predictor of failure? Finally, i fyou used failure of a single 
PTA procedure as your endpoint and not six as used in the 
paper, what would have been the failure rate? Certainly six 
procedures in 18 months, translated to six surgical proce- 
dures in that period of time, would have necessitated re- 
placement of the graft. 
Again, the authors are to be commended for helping to 
further defifie the ongoing problems associated with the 
arteriovenous fi tulas and their attendant problems. Thank 
you for the privilege of discussion. 
Dr. Alan B. Lumsden.  You raised some very impor- 
tant points. First of all, none of these were in fact fistulas. 
We confined ourselves to PTFE grafts. We excluded bo- 
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vine grafts, and we excluded all the autogenous fistulas. 
Your first question may be the most important. Why 50%? 
We chose 50% because if you look, the evolution of this 
concept basically begins with Schwab, who became inter- 
ested in maintenance of hemodialysis access grafts. At that 
point, he used 50% because he equated it with venous 
outflow pressure. That has essentialty been perpetuated 
down the line. Mmost all of the studies have then used 
50%. I certainly think you can argue with it. I am not sure, 
i fwe had used 80%, for example, whether we would have 
seen any efficacy from prophylactic intervention. I really 
don' t  know what the answer to that question is. The 
rationale for using 50% is because that was what all the 
nephrology data have used, and we wanted something that 
could be directly applied to the nephrology literature and 
that could equate with their previous tudies. 
Another question was about he functional parameters. 
There area whole variety of different ways in which neph- 
rologists attempt to use noninvasive methods for detecting 
the failing hemodialysis graft, measurement ofvenous out- 
flow pressure and urea recirculation, to name but two. You 
measure the pressure through the venous cannula at set 
dialysis flow rates. The ones we used were all measured at 
greater than 400 ta l /min.  You mcasurc the fraction of 
blood that is recirculating between the venous canula and 
the arterial canula, and it is supposed to imply downstream 
resistance causing recirculation of the blood; greater than 
15% is usually considered to be abnormal. More recently, 
people have just been using venous outflow pressures at 
slightly lower flow rates. We actually looked at all of these 
and really could not find any good association between the 
duplex-identified >50% stenoses and any of these physio- 
logie pressures. 
Your final question concerned what the result would 
have been i fwe had simply used one angioplasty instead 
of six as an end point. The average number  of angio- 
plasty procedures performed was close to two, it was 
1.94. Eight of these patients underwent more than two 
angioplasty procedures. The majority actually only un- 
derwent one angioplasty procedure. I don ' t  know what 
the answer to your question is. It is a very relevant one, 
and I think it is one that is worthwhile for us to go back 
and pull the data and look at it. I really cannot teil you 
what one angioplasty may or may not  have achieved in 
this group. 
Dr. Daniel  F. Fisher, Jr. (Chattanooga, Tenn.). You 
said that the majority of these grafts were 4-to-7 mm 
tapered grafts. Did you have enough of the ó mm grafts to 
look at the patency of ó mm versus 4-to-7 mm tapered 
grafts? 
Dr. Lumsden.  No, we really didn't. The rast majority 
of them »vere 4-to-7 mm taper grafts. 
Dr. Fisher. How did you revise the venous anastomo- 
sis when you had to operate on the group that had surgery? 
Did you use an interposition graft, or did you patch the 
venous anastomosis open? And do you think it makes any 
difference? 
Dr. Lumsden.  Weil, we did not actually operate on 
any of these patients. The endpoint of the trial was when 
the graft occluded. At that point, we would operate on 
rhein, but not under the basis of a trial. Then, it really 
ended up depending on an individual surgeon preference. 
What I do typically is cut down on the venous anastomosis 
and perform a thrombectomy, but then I routinely obtain 
on-table arteriograms and venograms. I started one time 
performing angioplasty in these venous anastomoses, and 
it really does not work. Having said that, i do think there is 
a role for endovascular techniques. I think the problem 
with the way that we tackle these is that we focus on the 
venous anastomosis and we ignore everything else. You 
would never dream of doing that in a failed femoropopli- 
teal graft. For some reason or another, we treat hese grafts 
differently. I think you should study the entire graft. I think 
the advantage of the potential endovascular pplication is 
to extend your reach to areas that you can't ger to and to 
the arterial end flow or into that central venous circulation. 
I think one problem is that addressing one lesion in a graft 
that clearly has multiple lesions is inadequate. 
Dr. Samuel P. Mart in  (Orlando, Fla.). I also very 
much enjoyed your paper. We have been concerned with 
this problem for some time. I was just wondering several 
things. First, when you performed your duplex scan, did 
you have a means of getting volume flow measurements 
with that? I was also concerned that, as you pointed out, 
there was a significant increased incidence ofgraft revisions 
in your group that underwent balloon angioplasty. I think 
that is a very significant number, 1 as opposed to 1.6 in that 
group. 
Second, on another point, I would like to know about 
your technique for balloon angioplasty. Some are perform- 
ing balloon angioplasty where the time of balloon dilata- 
tion is only a short time. They are doing this for less than a 
minute and point out that it is very important that this not 
be a sustained balloon inflation. They believe there can be 
injury with that, and they believe that just breaking cicatrix. 
I was wondering how you are performing your balloon 
angioplasty procedures, because certainly our results do 
significantly differ from some of these other observers. 
Dr. Lumsden.  Your first question was in regards to 
volume flow. We measured volume flow. There are formu- 
las for calculating this off the duplex data. It is a derived 
number, and I am not impressed that it is something that is 
particularly reliable. In looking at it, we really could not 
predict from the calculated volume flow whether it was 
>50% stenosis. As regards the number of revisions, that is a 
major concern, and in fact has led to a fairly contentious 
argument amongst the coäuthors here. This was a prospec- 
tive randomized study. We did not select these patients, 
and that may be a ctiticism. It is not easy to get all of this 
data in terms of number of graft revisions up front, and we 
did not stratify. As the chips fall in a prospective random- 
ized study, when we went back and looked at the number 
of revisions, that is one of the outcomes. That is going to 
be a criticism. I havc absolutely no doubt when this gets 
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published that that is the nail that the interventional radi- 
ology group is probably going to hang their hat on. How 
to defend that? You know, it is ditficult o defend. There 
are actually more stenoses, i fyou total them all up, in the 
observation group than there are in the angioplasty group. 
In that respect, it is a little weighted in terms of observa- 
tion, and in all of the function measurements that we did 
there is not really any difference. I agree, that is still a 
potential weakness in the interpretation f the study. 
Dr. Clifford J. Buckley (Temple, Tex.). One of the 
things that we have noticed in our own population of 
dialysis patients i  that in recent years the btood flow rate at 
which they are dialyzed has increased from 250 or 300 
tal /min to approximately 500 ml/min. We are observing 
increasing stenoses in the veins distal to the area of the 
outflow anastomosis between the fistula graft and the vein. 
Did you see this in your study group? It is important that 
you evaluate the outflow vein beyond the anastomotic 
area, because not uncommonly there may be a stenosis 
further up the vcin. I personally believe that this may be 
related to the high-volume flow and jet effect associated 
with it that results in injury to the vein wall. 
Dr. Ltunsden. I really have no idea whether it is 
related to higher-volume flow. We defined central venous 
stenosis as the distal axillal T vein and the subclavian rein. 
As you can see, there was a fairly significant number of 
those central venous stenoses in this particular group. I 
think you have touched on something that really only 
Beathard has tried to do and that is to try and classify these 
stenoses. We talk here about all stenoses as if they are 
equal, but they are clearly not equal; there are clearly some 
lesions that may be much more amenable to angioplasty 
than others, we just don't know what those are at the 
moment. 
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